These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12504667)

  • 1. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
    Arnould S; Hennebelle I; Canal P; Bugat R; Guichard S
    Eur J Cancer; 2003 Jan; 39(1):112-9. PubMed ID: 12504667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism.
    Lin S; Lei K; Du W; Yang L; Shi H; Gao Y; Yin P; Liang X; Liu J
    Int J Biochem Cell Biol; 2016 Feb; 71():24-34. PubMed ID: 26673998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
    Chen CC; Chen LT; Tsou TC; Pan WY; Kuo CC; Liu JF; Yeh SC; Tsai FY; Hsieh HP; Chang JY
    Br J Cancer; 2007 Aug; 97(3):334-44. PubMed ID: 17609664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
    Sark MW; Timmer-Bosscha H; Meijer C; Uges DR; Sluiter WJ; Peters WH; Mulder NH; de Vries EG
    Br J Cancer; 1995 Apr; 71(4):684-90. PubMed ID: 7710929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
    Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
    Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.
    Tassone P; Tagliaferri P; Galea E; Palmieri C; Bonelli P; Martelli ML; Tuccillo F; Turco MC; Venuta S
    Eur J Cancer; 2002 May; 38(8):1141-7. PubMed ID: 12008204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
    Los G; Mutsaers PH; Ruevekamp M; McVie JG
    Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
    Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
    J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
    Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
    Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.
    Zhou J; Zhou Y; Yin B; Hao W; Zhao L; Ju W; Bai C
    Oncol Rep; 2010 Jan; 23(1):121-8. PubMed ID: 19956872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
    Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
    Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.